Proof of Concept: Discover how we enhanced monoclonal antibody (mAb)?production in downstream processing
Introduction: Reshaping Bioprocessing with PAT
The biopharma industry is constantly seeking innovative tools to improve efficiency and precision in biomanufacturing. Monoclonal antibodies (mAbs) demand careful monitoring during downstream processing to maintain quality and ensure consistency. In collaboration with Merck Serono Healthcare, we showcased how our cutting-edge Process Analytical Technology (PAT), Monipa, enables successful monitoring of mAb concentration after purification steps.
The Study: Inline Monitoring after Chromatography Step
Traditional methods of monitoring mAb concentrations often involve offline sampling, which can be time-consuming and prone to delays. Our Monipa was connected inline to the chromatographic system, ?kta Pure, providing continuous, real-time measurements.?
The Impact: Accelerating the Production of Life-Saving Medicines
Biopharma continues to innovate every single day. Every breakthrough brings us closer to transforming patient care, but it also demands novel solutions. By avoiding manual sampling and providing real-time results, our technology not only improves accuracy but also accelerates critical bioprocessing steps. This positions Monipa as a trustworthy solution for tackling the industry’s growing demands.
?
Want to explore more how Monipa can elevate your bioprocesses??Click below?to read the full study:
Marasca et al. Towards continuous biomanufacturing: Real-time monitoring of protein concentration in downstream processing by mid-infrared spectroscopy. Poster presented at: BPI Europe 2023; May 9-12, 2023; Amsterdam, the Netherlands.
?Let’s connect and discuss more about our applications!?
?? Schedule a meeting via [email protected]
?? Subscribe to our newsletter for the latest Monipa updates, industry insights, and more.
?